NASDAQ:AIMT - Aimmune Therapeutics Stock Price, Price Target & More

$31.68 -0.27 (-0.85 %)
(As of 04/24/2018 04:00 PM ET)
Previous Close$31.95
Today's Range$31.35 - $32.05
52-Week Range$15.97 - $42.00
Volume342,714 shs
Average Volume932,293 shs
Market Capitalization$1.84 billion
P/E Ratio-12.16
Dividend YieldN/A
Beta-0.37

About Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics logoAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. The company has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Receive AIMT News and Ratings via Email

Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AIMT
CUSIPN/A
Phone650-614-5220

Debt

Debt-to-Equity RatioN/A
Current Ratio7.11%
Quick Ratio7.11%

Price-To-Earnings

Trailing P/E Ratio-12.16
Forward P/E Ratio-11.65
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.50 per share
Price / Book9.05

Profitability

EPS (Most Recent Fiscal Year)($2.61)
Net Income$-131,320,000.00
Net MarginsN/A
Return on Equity-59.03%
Return on Assets-53.97%

Miscellaneous

Employees131
Outstanding Shares58,020,000

How to Become a New Pot Stock Millionaire

Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions

What is Aimmune Therapeutics' stock symbol?

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics (NASDAQ:AIMT) posted its quarterly earnings results on Monday, March, 12th. The biotechnology company reported ($0.81) EPS for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.09. View Aimmune Therapeutics' Earnings History.

What price target have analysts set for AIMT?

8 brokerages have issued 12 month price targets for Aimmune Therapeutics' stock. Their predictions range from $30.00 to $80.00. On average, they expect Aimmune Therapeutics' share price to reach $60.1250 in the next twelve months. View Analyst Ratings for Aimmune Therapeutics.

What are Wall Street analysts saying about Aimmune Therapeutics stock?

Here are some recent quotes from research analysts about Aimmune Therapeutics stock:
  • 1. Cantor Fitzgerald analysts commented, "Quick thoughts on today’s market reaction. Absent hearing pointed criticism of the PALISADE data, the market’s reaction befuddles us somewhat. We suppose AIMT owners could be taking profits, the stock is +50% since October 20, 2017, as compared with +1% for the NBI. Would-be investors might be disinclined to buy the stock on release of positive top-line results that were anticipated (in one fashion of another) and might desire a view of additional data. We are mindful, too, that the commercial launch of the product is likely 15-18 months hence." (2/20/2018)
  • 2. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (1/31/2018)

Who are some of Aimmune Therapeutics' key competitors?

Who are Aimmune Therapeutics' key executives?

Aimmune Therapeutics' management team includes the folowing people:
  • Dr. Stephen George Dilly, Pres, CEO & Director (Age 58)
  • Mr. Jeffrey H. Knapp, Chief Operating Officer (Age 52)
  • Dr. Daniel C. Adelman M.D., Chief Medical Officer (Age 61)
  • Mr. Eric H. Bjerkholt, CFO & Principal Accounting Officer (Age 58)
  • Dr. Laura Hansen Ph.D., VP of Investor Relations

When did Aimmune Therapeutics IPO?

(AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO.

Has Aimmune Therapeutics been receiving favorable news coverage?

Media stories about AIMT stock have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aimmune Therapeutics earned a media sentiment score of 0.24 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.05 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Aimmune Therapeutics' major shareholders?

Aimmune Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (5.05%) and FMR LLC (5.05%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Foresite Capital Fund Ii, LP, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics.

How do I buy shares of Aimmune Therapeutics?

Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aimmune Therapeutics' stock price today?

One share of AIMT stock can currently be purchased for approximately $31.68.

How big of a company is Aimmune Therapeutics?

Aimmune Therapeutics has a market capitalization of $1.84 billion. The biotechnology company earns $-131,320,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Aimmune Therapeutics employs 131 workers across the globe.

How can I contact Aimmune Therapeutics?

Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]


MarketBeat Community Rating for Aimmune Therapeutics (AIMT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  230 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  368
MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aimmune Therapeutics (NASDAQ:AIMT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Aimmune Therapeutics in the last 12 months. Their average twelve-month price target is $60.1250, suggesting that the stock has a possible upside of 89.79%. The high price target for AIMT is $80.00 and the low price target for AIMT is $30.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $60.1250$60.1250$59.00$51.00
Price Target Upside: 89.79% upside67.15% upside51.28% upside98.75% upside

Aimmune Therapeutics (NASDAQ:AIMT) Consensus Price Target History

Price Target History for Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics (NASDAQ:AIMT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2018Piper JaffraySet Price TargetBuy$62.00LowView Rating Details
3/6/2018WedbushReiterated RatingOutperform$72.00HighView Rating Details
3/5/2018Credit Suisse GroupSet Price TargetOutperform -> Buy$45.00 -> $47.00MediumView Rating Details
3/5/2018Roth CapitalBoost Price TargetBuy$75.00 -> $80.00LowView Rating Details
3/5/2018Cantor FitzgeraldReiterated RatingOverweight$64.00LowView Rating Details
2/27/2018Royal Bank of CanadaBoost Price TargetOutperform$62.00MediumView Rating Details
2/20/2018Deutsche BankSet Price TargetBuy$30.00HighView Rating Details
12/20/2017Robert W. BairdInitiated CoverageOutperform -> Outperform$64.00MediumView Rating Details
9/26/2016JMP SecuritiesInitiated CoverageOutperform$30.00N/AView Rating Details
5/16/2016Bank of AmericaReiterated RatingBuyN/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Aimmune Therapeutics (NASDAQ:AIMT) Earnings History and Estimates Chart

Earnings by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics (NASDAQ:AIMT) Earnings Estimates

2018 EPS Consensus Estimate: ($2.92)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.72)($0.72)($0.72)
Q2 20181($0.73)($0.73)($0.73)
Q3 20181($0.73)($0.73)($0.73)
Q4 20181($0.74)($0.74)($0.74)

Aimmune Therapeutics (NASDAQ AIMT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018Q4 2017($0.72)($0.81)ViewN/AView Earnings Details
11/6/2017Q3 2017($0.72)($0.63)ViewN/AView Earnings Details
8/8/2017Q2($0.64)($0.65)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.57)($0.52)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.47)($0.55)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.4460)($0.53)ViewN/AView Earnings Details
8/10/2016Q216($0.42)($0.43)ViewN/AView Earnings Details
5/16/2016Q116($0.40)($0.37)ViewN/AView Earnings Details
3/3/2016Q415($0.35)($0.39)ViewListenView Earnings Details
11/4/2015Q3 2015($0.24)($0.36)ViewN/AView Earnings Details
8/31/2015Q2 2015($1.60)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aimmune Therapeutics (NASDAQ:AIMT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aimmune Therapeutics (NASDAQ AIMT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.70%
Institutional Ownership Percentage: 64.35%
Insider Trading History for Aimmune Therapeutics (NASDAQ:AIMT)
Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics (NASDAQ AIMT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/5/2018Douglas T SheehyInsiderSell3,523$36.52$128,659.9632,500View SEC Filing  
3/1/2018Mary M RozenmanInsiderSell1,807$33.10$59,811.70View SEC Filing  
2/26/2018Eric BjerkholtCFOBuy3,125$32.00$100,000.00View SEC Filing  
2/26/2018Kathryn E FalbergDirectorBuy30,000$32.00$960,000.00View SEC Filing  
2/22/2018Bakker Juliet TammenomsMajor ShareholderBuy9,375$32.00$300,000.0016,651View SEC Filing  
2/22/2018Patrick G EnrightDirectorBuy15,593$32.00$498,976.0022,869View SEC Filing  
2/5/2018Douglas T SheehyInsiderSell1,648$35.87$59,113.76View SEC Filing  
2/1/2018Mary M RozenmanInsiderSell6,592$35.36$233,093.12View SEC Filing  
1/24/2018Douglas T SheehyInsiderSell1,875$38.15$71,531.251,875View SEC Filing  
1/16/2018Daniel C Md AdelmanInsiderSell9,933$40.00$397,320.0026,784View SEC Filing  
1/12/2018Daniel C Md AdelmanInsiderSell26,784$40.00$1,071,360.0026,784View SEC Filing  
1/4/2018Douglas T SheehyInsiderSell1,648$37.33$61,519.841,648View SEC Filing  
1/2/2018Susan E BarrowcliffeInsiderSell75,000$37.14$2,785,500.00View SEC Filing  
12/27/2017Daniel C Md AdelmanInsiderSell3,283$40.00$131,320.003,283View SEC Filing  
12/26/2017Douglas T SheehyInsiderSell1,875$39.44$73,950.001,875View SEC Filing  
12/4/2017Douglas T SheehyInsiderSell1,906$38.66$73,685.961,906View SEC Filing  
11/30/2017Douglas T SheehyInsiderSell3,750$37.00$138,750.003,750View SEC Filing  
11/9/2017Douglas T SheehyInsiderSell1,905$33.00$62,865.001,905View SEC Filing  
10/23/2017Douglas T SheehyInsiderSell47,425$34.44$1,633,317.0034,300View SEC Filing  
10/16/2017Stephen George DillyCEOSell1,154$26.24$30,280.96View SEC Filing  
10/6/2017Stephen George DillyCEOSell4,047$26.31$106,476.57View SEC Filing  
10/5/2017Stephen George DillyCEOSell14,689$26.24$385,439.36View SEC Filing  
10/4/2017Stephen George DillyCEOSell80,110$26.23$2,101,285.30View SEC Filing  
9/25/2017Stephen George DillyCEOSell100,000$25.01$2,501,000.00View SEC Filing  
9/25/2017Susan E BarrowcliffeInsiderSell20,000$25.00$500,000.0020,000View SEC Filing  
9/7/2017Mary M RozenmanInsiderSell30,000$22.50$675,000.0030,129View SEC Filing  
9/6/2017Susan E BarrowcliffeInsiderSell18,390$22.00$404,580.003,223View SEC Filing  
7/27/2017Susan E BarrowcliffeInsiderSell500$22.00$11,000.00500View SEC Filing  
7/26/2017Stephen George DillyInsiderSell50,000$21.46$1,073,000.00View SEC Filing  
7/25/2017Susan E BarrowcliffeInsiderSell6,110$22.00$134,420.00960View SEC Filing  
7/21/2017Douglas T. SheehyInsiderSell7,460$21.66$161,583.60View SEC Filing  
7/17/2017Mary M RozenmanInsiderSell14,940$21.44$320,313.609,103View SEC Filing  
7/5/2017Mary M RozenmanInsiderSell45,060$20.85$939,501.0030,129View SEC Filing  
7/3/2017Susan E BarrowcliffeInsiderSell15,000$20.26$303,900.0015,000View SEC Filing  
6/23/2017Stephen George DillyInsiderSell49,400$20.21$998,374.00View SEC Filing  
5/12/2017Eric BjerkholtCFOBuy5,000$19.84$99,200.005,000View SEC Filing  
5/10/2017Stephen George DillyInsiderSell600$20.15$12,090.00View SEC Filing  
4/3/2017Warren L DesouzaCFOSell15,000$21.58$323,700.0035,681View SEC Filing  
3/21/2017Warren L DesouzaCFOSell10,000$22.95$229,500.0030,681View SEC Filing  
11/4/2016Mary M RozenmanInsiderSell24,096$17.60$424,089.6024,096View SEC Filing  
10/5/2016Mary M RozenmanInsiderSell25,000$16.80$420,000.0025,000View SEC Filing  
9/8/2016Mary M RozenmanInsiderSell30,000$16.80$504,000.0030,000View SEC Filing  
5/31/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell240,000$15.23$3,655,200.00View SEC Filing  
3/29/2016Longitude Capital Partners Ii,Major ShareholderBuy78,504$13.87$1,088,850.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aimmune Therapeutics (NASDAQ AIMT) News Headlines

Source:
DateHeadline
Backing Blackstone For A Decade - Cramers Lightning Round (4/23/18)Backing Blackstone For A Decade - Cramer's Lightning Round (4/23/18)
seekingalpha.com - April 24 at 8:30 AM
Global Peanut Allergy Therapeutics - 2018 Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations ...Global Peanut Allergy Therapeutics - 2018 Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations ...
www.businesswire.com - April 21 at 8:31 AM
Market Trends Toward New Normal in Genuine Parts, Energizer, Arthur J ...Market Trends Toward New Normal in Genuine Parts, Energizer, Arthur J ...
globenewswire.com - April 20 at 5:11 PM
Market Trends Toward New Normal in Genuine Parts, Energizer, Arthur J. Gallagher, Aimmune Therapeutics, Roku, and Premier — Emerging Consolidated Expectations, Analyst RatingsMarket Trends Toward New Normal in Genuine Parts, Energizer, Arthur J. Gallagher, Aimmune Therapeutics, Roku, and Premier — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - April 19 at 8:30 AM
Aimmune Therapeutics (AIMT) Given Average Rating of "Buy" by BrokeragesAimmune Therapeutics (AIMT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 16 at 1:44 AM
 Brokerages Expect Aimmune Therapeutics (AIMT) Will Announce Earnings of -$0.66 Per Share Brokerages Expect Aimmune Therapeutics (AIMT) Will Announce Earnings of -$0.66 Per Share
www.americanbankingnews.com - April 10 at 9:13 PM
Aimmune Therapeutics (AIMT) Given Outperform Rating at WedbushAimmune Therapeutics (AIMT) Given Outperform Rating at Wedbush
www.americanbankingnews.com - April 6 at 11:11 AM
Aimmune Therapeutics (AIMT) PT Set at $62.00 by Piper JaffrayAimmune Therapeutics (AIMT) PT Set at $62.00 by Piper Jaffray
www.americanbankingnews.com - April 5 at 12:03 PM
Aimmune Therapeutics (AIMT) Rating Increased to Buy at ValuEngineAimmune Therapeutics (AIMT) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 8:10 PM
Is This Why AnaptysBio Inc. Fell on Monday?Is This Why AnaptysBio Inc. Fell on Monday?
finance.yahoo.com - April 3 at 8:39 AM
Aimmune Therapeutics (AIMT) Cut to "Hold" at BidaskClubAimmune Therapeutics (AIMT) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 30 at 6:16 PM
Credit Suisse Group Analysts Give Aimmune Therapeutics (AIMT) a $45.00 Price TargetCredit Suisse Group Analysts Give Aimmune Therapeutics (AIMT) a $45.00 Price Target
www.americanbankingnews.com - March 28 at 7:04 PM
Protecting children from severe peanut allergiesProtecting children from severe peanut allergies
finance.yahoo.com - March 27 at 5:03 PM
U.S. Biotech/Pharma Sector Daily Observations Letter: March 26, 2018U.S. Biotech/Pharma Sector Daily Observations Letter: March 26, 2018
seekingalpha.com - March 27 at 8:44 AM
After-hours buzz: RHT, ANAB & moreAfter-hours buzz: RHT, ANAB & more
finance.yahoo.com - March 27 at 8:44 AM
Aimmune Therapeutics (AIMT) Downgraded by BidaskClub to SellAimmune Therapeutics (AIMT) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - March 26 at 3:13 PM
Aimmune Therapeutics (AIMT) Now Covered by Royal Bank of CanadaAimmune Therapeutics (AIMT) Now Covered by Royal Bank of Canada
www.americanbankingnews.com - March 25 at 8:16 AM
Credit Suisse Group Reiterates "$45.00" Price Target for Aimmune Therapeutics (AIMT)Credit Suisse Group Reiterates "$45.00" Price Target for Aimmune Therapeutics (AIMT)
www.americanbankingnews.com - March 24 at 8:55 PM
Aimmune Therapeutics Inc (AIMT) Given Average Rating of "Buy" by BrokeragesAimmune Therapeutics Inc (AIMT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 22 at 1:36 AM
Wedbush Research Analysts Lift Earnings Estimates for Aimmune Therapeutics Inc (AIMT)Wedbush Research Analysts Lift Earnings Estimates for Aimmune Therapeutics Inc (AIMT)
www.americanbankingnews.com - March 19 at 2:14 AM
AIMMUNE THERAPEUTICS, INC. - StreetInsider.comAIMMUNE THERAPEUTICS, INC. - StreetInsider.com
www.streetinsider.com - March 13 at 8:41 AM
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results - Business Wire (press release)Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results - Business Wire (press release)
www.businesswire.com - March 13 at 8:41 AM
Aimmune Therapeutics Inc (AIMT) Short Interest Up 49.0% in FebruaryAimmune Therapeutics Inc (AIMT) Short Interest Up 49.0% in February
www.americanbankingnews.com - March 13 at 1:53 AM
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial ResultsAimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 12 at 11:01 AM
Zacks: Brokerages Expect Aimmune Therapeutics Inc (AIMT) Will Post Earnings of -$0.70 Per ShareZacks: Brokerages Expect Aimmune Therapeutics Inc (AIMT) Will Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - March 7 at 3:18 PM
Aimmune Therapeutics to Participate in Four Investor Conferences in March - Business Wire (press release)Aimmune Therapeutics to Participate in Four Investor Conferences in March - Business Wire (press release)
www.businesswire.com - March 7 at 8:38 AM
Aimmune Therapeutics to Participate in Four Investor Conferences in MarchAimmune Therapeutics to Participate in Four Investor Conferences in March
finance.yahoo.com - March 7 at 8:38 AM
Cantor Fitzgerald Analysts Lower Earnings Estimates for Aimmune Therapeutics Inc (AIMT)Cantor Fitzgerald Analysts Lower Earnings Estimates for Aimmune Therapeutics Inc (AIMT)
www.americanbankingnews.com - March 7 at 7:26 AM
Douglas T. Sheehy Sells 3,523 Shares of Aimmune Therapeutics Inc (AIMT) StockDouglas T. Sheehy Sells 3,523 Shares of Aimmune Therapeutics Inc (AIMT) Stock
www.americanbankingnews.com - March 6 at 9:44 PM
Aimmune Therapeutics (AIMT) Receives "Outperform" Rating from WedbushAimmune Therapeutics (AIMT) Receives "Outperform" Rating from Wedbush
www.americanbankingnews.com - March 6 at 2:17 PM
Your Daily Pharma Scoop: Aimmune Data, Onconova Shares Get A Boost, G1 Therapeutics Positive Data - Seeking AlphaYour Daily Pharma Scoop: Aimmune Data, Onconova Shares Get A Boost, G1 Therapeutics' Positive Data - Seeking Alpha
seekingalpha.com - March 6 at 8:31 AM
Aimmune Therapeutics Inc (AIMT) Insider Mary M. Rozenman Sells 1,807 SharesAimmune Therapeutics Inc (AIMT) Insider Mary M. Rozenman Sells 1,807 Shares
www.americanbankingnews.com - March 5 at 7:34 PM
Aimmune Therapeutics (AIMT) Stock Rating Reaffirmed by Cantor FitzgeraldAimmune Therapeutics (AIMT) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - March 5 at 5:34 PM
Aimmune Therapeutics (AIMT) PT Set at $47.00 by Credit Suisse GroupAimmune Therapeutics (AIMT) PT Set at $47.00 by Credit Suisse Group
www.americanbankingnews.com - March 5 at 4:30 PM
Roth Capital Raises Aimmune Therapeutics (AIMT) Price Target to $80.00Roth Capital Raises Aimmune Therapeutics (AIMT) Price Target to $80.00
www.americanbankingnews.com - March 5 at 9:45 AM
Aimmune Therapeutics (AIMT) Reports Positive Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy - StreetInsider.comAimmune Therapeutics (AIMT) Reports Positive Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy - StreetInsider.com
www.streetinsider.com - March 5 at 8:35 AM
Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAOAimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO
finance.yahoo.com - March 4 at 6:14 PM
Aimmune Therapeutics: Insider Buying Alert - Seeking AlphaAimmune Therapeutics: Insider Buying Alert - Seeking Alpha
seekingalpha.com - March 4 at 8:33 AM
Aimmune Therapeutics (AIMT) Stock Rating Upgraded by BidaskClubAimmune Therapeutics (AIMT) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 4 at 12:16 AM
Aimmune Therapeutics Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common StockAimmune Therapeutics Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
finance.yahoo.com - March 2 at 5:54 PM
Peanut Allergy-Focused Biotech May Strike Magic in OrlandoPeanut Allergy-Focused Biotech May Strike Magic in Orlando
finance.yahoo.com - March 2 at 5:54 PM
Aimmune Therapeutics to Host Analyst and Investor Event Following ... - Business Wire (press release)Aimmune Therapeutics to Host Analyst and Investor Event Following ... - Business Wire (press release)
www.businesswire.com - March 1 at 8:27 AM
Aimmune Therapeutics (AIMT) Given New $62.00 Price Target at Royal Bank of CanadaAimmune Therapeutics (AIMT) Given New $62.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - February 27 at 3:32 PM
Aimmune Therapeutics (AIMT) Given a $62.00 Price Target at Piper Jaffray CompaniesAimmune Therapeutics (AIMT) Given a $62.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - February 27 at 3:31 PM
Oversold Conditions For Aimmune Therapeutics (AIMT)Oversold Conditions For Aimmune Therapeutics (AIMT)
www.nasdaq.com - February 27 at 8:35 AM
Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI-WAO Joint Congress in OrlandoAimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI-WAO Joint Congress in Orlando
finance.yahoo.com - February 27 at 8:35 AM
Insider Buying: Aimmune Therapeutics Inc (AIMT) CFO Acquires 3,125 Shares of StockInsider Buying: Aimmune Therapeutics Inc (AIMT) CFO Acquires 3,125 Shares of Stock
www.americanbankingnews.com - February 26 at 9:22 PM
Aimmune Therapeutics Inc (AIMT) Director Purchases $498,976.00 in StockAimmune Therapeutics Inc (AIMT) Director Purchases $498,976.00 in Stock
www.americanbankingnews.com - February 26 at 6:34 PM
Insider Buying: Aimmune Therapeutics Inc (AIMT) Major Shareholder Buys 9,375 Shares of StockInsider Buying: Aimmune Therapeutics Inc (AIMT) Major Shareholder Buys 9,375 Shares of Stock
www.americanbankingnews.com - February 26 at 6:34 PM
Insider Buying: Aimmune Therapeutics Inc (AIMT) Director Acquires 30,000 Shares of StockInsider Buying: Aimmune Therapeutics Inc (AIMT) Director Acquires 30,000 Shares of Stock
www.americanbankingnews.com - February 26 at 6:18 PM

SEC Filings

Aimmune Therapeutics (NASDAQ:AIMT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aimmune Therapeutics (NASDAQ:AIMT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aimmune Therapeutics (NASDAQ AIMT) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.